Last reviewed · How we verify
NCT03645850
Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness
NA trial testing Vismed gel Multi 0.3% eye drops in Dry Eye in 80 participants. Status unknown.
1 March 2019
Quick facts
| Lead sponsor | Horus Pharma |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 80 |
| Start date | 1 September 2018 |
| Primary completion | 1 March 2019 |
| Estimated completion | 15 June 2019 |
Drugs / interventions tested
- Vismed gel Multi 0.3% eye drops
- Vismed Multi 0.18% eye drops
Conditions studied
- Dry Eye — all drugs for Dry Eye →
Sponsor
Horus Pharma
Who can join
18 and older, any sex, with Dry Eye. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicentric, comparative, randomized, investigator-blinded, parallel group study to demonstrate the non-inferiority of Vismed® Gel Multi 0.3% in comparison with Vismed® Multi 0.18% in terms of cornea and conjunctiva staining (Oxford score) on patients with moderate to severe ocular dryness, after 35 days of treatment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Sodium hyaluronate 0.30% ocular gel versus sodium hyaluronate 0.18% eye drop in the treatment of moderate to severe dry eye disease.
Calonge M, Sahyoun M, Baillif S, Gain P, et al · · 2023 · cited 8× · PMID 35450456 · DOI 10.1177/11206721221096321
Verify or expand the search:
- PubMed search for NCT03645850
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dry Eye
Currently open trials in the same condition.
- NCT07366944 — PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes · NA · recruiting
- NCT07329712 — Comparing Tear Proteomics Profile in Dry Eye Disease pre-and Post-treatment With Low Level Light Therapy · recruiting
- NCT07266948 — Impact of TRYPTYR on a Patient's Quality of Life and Ability to Perform Work · Phase 4 · recruiting
- NCT07298811 — Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment · Phase 1, PHASE2 · recruiting
- NCT07135193 — Evaluation of the Protective Effects of Cordyceps Cicadae on Visual Function and Anti-Fatigue Performance in Esports Ath · NA · active not recruiting
Other Horus Pharma trials
Trials by the same sponsor.
- NCT06607237 — Evaluation of Safety and Efficacy of DM-28 for Treatment of Moderate to Severe Ocular Dryness · NA · completed
- NCT06245421 — Evaluation of the Efficacy and Safety of DM934 Versus Théalose on Eye Dryness · NA · completed
- NCT03517748 — Evaluation of the Efficacy and Safety of DM05 Versus Optive™ on the Treatment of Moderate to Severe Ocular Dryness · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03645850 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Horus Pharma
- Last refreshed: 24 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03645850.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing